S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
NASDAQ:VXRT

Vaxart Stock Forecast, Price & News

$8.17
-0.28 (-3.31 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.11
$8.39
50-Day Range
$7.19
$9.80
52-Week Range
$3.50
$24.90
Volume2.27 million shs
Average Volume13.61 million shs
Market Capitalization$1.02 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.31
30 days | 90 days | 365 days | Advanced Chart
Receive VXRT News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter.


Vaxart logo

About Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.84 out of 5 stars

Medical Sector

732nd out of 1,352 stocks

Biological Products, Except Diagnostic Industry

111th out of 195 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Vaxart (NASDAQ:VXRT) Frequently Asked Questions

Is Vaxart a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Vaxart stock.
View analyst ratings for Vaxart
or view top-rated stocks.

What stocks does MarketBeat like better than Vaxart?

Wall Street analysts have given Vaxart a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vaxart wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Vaxart's next earnings date?

Vaxart is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Vaxart
.

How were Vaxart's earnings last quarter?

Vaxart, Inc. (NASDAQ:VXRT) posted its earnings results on Thursday, August, 5th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.01. The biotechnology company earned $0.11 million during the quarter, compared to the consensus estimate of $0.55 million. Vaxart had a negative net margin of 4,363.92% and a negative trailing twelve-month return on equity of 34.27%.
View Vaxart's earnings history
.

How has Vaxart's stock been impacted by COVID-19 (Coronavirus)?

Vaxart's stock was trading at $2.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VXRT shares have increased by 294.7% and is now trading at $8.17.
View which stocks have been most impacted by COVID-19
.

When did Vaxart's stock split? How did Vaxart's stock split work?

Shares of Vaxart reverse split on the morning of Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

What price target have analysts set for VXRT?

3 analysts have issued 12-month target prices for Vaxart's stock. Their forecasts range from $9.00 to $18.00. On average, they expect Vaxart's stock price to reach $13.33 in the next year. This suggests a possible upside of 63.2% from the stock's current price.
View analysts' price targets for Vaxart
or view top-rated stocks among Wall Street analysts.

Who are Vaxart's key executives?

Vaxart's management team includes the following people:
  • Andrei Floroiu, President CEO, CFO & Director
  • Sean N. Tucker, Chief Scientific Officer & Senior Vice President
  • Richard Schwartz, Senior Vice President-Technical Operations
  • Shaily Jaini Garg, SVP-Clinical Development & Project Management
  • Margaret A. Echerd, Chief Accounting Officer & Senior Vice President

What other stocks do shareholders of Vaxart own?

What is Vaxart's stock symbol?

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Who are Vaxart's major shareholders?

Vaxart's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.65%), State Street Corp (6.06%), Vanguard Group Inc. (4.78%), Geode Capital Management LLC (1.65%), Susquehanna International Group LLP (0.00%) and Northern Trust Corp (1.00%). Company insiders that own Vaxart stock include Armistice Capital Master Fund, Armistice Capital, Llc, John P Richard, Margaret Echerd, Robert A Yedid, Sean Tucker, Todd C Davis and Wouter Latour.
View institutional ownership trends for Vaxart
.

Which major investors are selling Vaxart stock?

VXRT stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Principal Financial Group Inc., Rafferty Asset Management LLC, FMR LLC, Bank of Montreal Can, Wells Fargo & Company MN, Bailard Inc., and National Asset Management Inc.. Company insiders that have sold Vaxart company stock in the last year include Margaret Echerd, Robert A Yedid, Sean Tucker, and Wouter Latour.
View insider buying and selling activity for Vaxart
or view top insider-selling stocks.

Which major investors are buying Vaxart stock?

VXRT stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Northern Trust Corp, GMT Capital Corp, Vanguard Group Inc., Nuveen Asset Management LLC, Citadel Advisors LLC, and Charles Schwab Investment Management Inc.. Company insiders that have bought Vaxart stock in the last two years include Armistice Capital Master Fund, John P Richard, and Wouter Latour.
View insider buying and selling activity for Vaxart
or or view top insider-buying stocks.

How do I buy shares of Vaxart?

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaxart's stock price today?

One share of VXRT stock can currently be purchased for approximately $8.17.

How much money does Vaxart make?

Vaxart has a market capitalization of $1.02 billion and generates $4.05 million in revenue each year. The biotechnology company earns $-32,220,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

How many employees does Vaxart have?

Vaxart employs 28 workers across the globe.

What is Vaxart's official website?

The official website for Vaxart is www.vaxart.com.

Where are Vaxart's headquarters?

How can I contact Vaxart?

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at (650) 550-3500 or via email at [email protected].


This page was last updated on 9/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.